scispace - formally typeset
U

Uwe Rudolph

Researcher at University of Illinois at Urbana–Champaign

Publications -  203
Citations -  18044

Uwe Rudolph is an academic researcher from University of Illinois at Urbana–Champaign. The author has contributed to research in topics: GABAA receptor & Receptor. The author has an hindex of 66, co-authored 194 publications receiving 16779 citations. Previous affiliations of Uwe Rudolph include ETH Zurich & University of Zurich.

Papers
More filters
Journal ArticleDOI

Benzodiazepine actions mediated by specific γ-aminobutyric acid A receptor subtypes

TL;DR: In this article, a histidine-to-arginine point mutation at position 101 of the murine α1-subunit gene was found to render α-type GABAA receptors insensitive to allosteric modulation by benzodiazepine-site ligands, whilst regulation by the physiological neurotransmitter γ-aminobutyric acid is preserved.
Journal ArticleDOI

Molecular and neuronal substrate for the selective attenuation of anxiety.

TL;DR: The findings indicate that the anxiolytic effect of benzodiazepine drugs is mediated by alpha2 GABAA receptors, which are largely expressed in the limbic system, but not by alpha3 GAB AA receptors,Which predominate in the reticular activating system.
Journal ArticleDOI

Molecular and neuronal substrates for general anaesthetics.

TL;DR: The neuronal systems that are thought to be involved in mediating clinically relevant actions of general anaesthetics are described and how the function of individual drug targets, in particular GABAA-receptor subtypes, can be revealed by genetic studies in vivo is discussed.
Journal ArticleDOI

A New Benzodiazepine Pharmacology

TL;DR: Rational drug targeting to specific receptor subtypes has now become possible, and only restricted neuronal networks will be modulated by the new subtype-selective drugs.
Journal ArticleDOI

Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.

TL;DR: The identification of separable key functions of GABAA receptor subtypes suggests that receptor subtype-selective compounds could overcome the limitations of classical benzodiazepines; furthermore, they might be valuable for novel indications such as chronic pain, depression, schizophrenia, cognitive enhancement and stroke.